Wechselwirkungen · Voriconazole Hikma (previously Voriconazole Hospira)
Voriconazole Hikma 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 14
HOS-130951 · Präparat HOS-096981
Low dose (100 mg BID)* Ritonavir Cmax ↓ 25% Coadministration of voriconazole Ritonavir AUCτ ↓13% and low-dose ritonavir (100 mg Voriconazole Cmax ↓ 24% BID) should be avoided unless Voriconazole AUCτ ↓ 39% an assessment of the benefit/risk to the patient justifies the use of voriconazole. Other HIV Protease Inhibitors Not studied clinically. In vitro Careful monitoring for any (including but not limited to: studies show that voriconazole may occurrence of drug toxicity saquinavir, amprenavir and inhibit the metabolism of HIV and/or lack of efficacy, and dose nelfinavir)* protease inhibitors and the adjustment may be needed. [CYP3A4 substrates and metabolism of voriconazole may inhibitors] also be inhibited by HIV protease inhibitors. Efavirenz (a non-nucleoside reverse transcriptase inhibitor, (NNRTI)) [CYP450 inducer; CYP3A4 inhibitor and substrate]
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): nelfinavir (HOS-084520) protease (HOS-085623) saquinavir (HOS-084522) amprenavir (HOS-086183) efavirenz (HOS-087947) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-23T14:40:00Z · SHA-256 8f5a567ef9a1f0f0bee27abd2100fc7726dcc5281b72b1f33957fd6bcec22b38 · Passage 02ee4af13a4918d8b9cedecc25198b586102a0c79dcf89bcc46547ce173c043b · Zeichen 15666–16959 im Abschnitt